VivoSeq
Other

NSCLC, Stage IB-IIIA

5

Pipeline Programs↗

1

Active Trials↗

4

Companies Involved↗

NSCLC, Stage IB-IIIA is an early-stage landscape with 5 programs across 4 companies. The most active players are Taiho Oncology, Inc., McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc., Avyxa. 5 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

28/100

Pipeline Velocity

6/100

Mech. Concentration

100/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Taiho Oncology, Inc. logo

Taiho Oncology, Inc.

2 programs

Phase 3M

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

1 program

Phase 3A

Avyxa

1 program

Phase 3G

Gynecologic Oncology Group

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Trial Status

1

clinical trials

Active, not recruiting1 · 100%

Clinical Trials

Trial Activity

A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Phase 3 Study of Zipalertinib Plus Adjuvant Chemotherapy Versus Placebo Plus Adjuvant Chemotherapy in Stage IB-IIIA NSCLC Patients With Uncommon EGFR Mutations Following Complete Tumor Resection (REZILIENT4)
Active, not recruiting·Taiho Oncology, Inc. logoTaiho Oncology, Inc.·Phase 3·NCT07128199·360 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)